Mari / iStockphoto.com
The US Court of Appeals for the Federal Circuit has remanded a decision to the Patent Trial and Appeal Board (PTAB) concerning a dispute between LA Biomedical Research Institute and Eli Lilly.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Federal Circuit, IPR, inter partes review, patent, Eli Lilly, LA Biomedical Research, PTAB, Patent Trial and Appeal Board, Cialis